Avinza® (Morphine Sulfate Extended-Release Capsules)

Kathy Wilkinson

Cynthia R. King

Ashkan Khabazian

analgesics, opioid, morphine derivatives
CJON 2003, 7(4), 458-478. DOI: 10.1188/03.CJON.458-460

Jump to a section

    References

    Anderson, G., Christrup, L., & Sjogren, P. (2003). Relationship among morphine metabolism, pain, and side effects during long-term treatment: An update. Journal of Pain and Symptom Management, 25, 74-91.

    Caldwell, J., Rapoport, R., Davis, J., Offenberg, H., Marker, H., Roth, S., et al. (2002). Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: Results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. Journal of Pain and Symptom Management, 23, 278-291.

    Eliot, L., Cato, A., Geiser, R., & Loewen, G. (2002). Evaluation of two loading-dose regimens of Morphelan in healthy volunteers. Journal of Applied Research, 2, 1-8.

    Eliot, L., Geiser, R., & Loewen, G. (2001). Steady-state pharmacokinetic comparison of a new, once-daily, extended-release morphine formulation (Morphelan) and Oxycontin twice daily. Journal of Oncology Pharmacy Practice, 7, 1-8.

    Ligand Pharmaceuticals, Inc. (2002). Avinzar. Retrieved June 20, 2003, from http://www.ligand.com/pdf/AVINZAPI040302.pdf

    Ligand Pharmacauticals, Inc. (2002). Avinza® (morphine sulfate extended-release capsules) product monograph. San Diego, CA: Author.

    Portenoy, R., Sciberras, A., Eliot, L., Loewen, G., Butler, J., & Devane, J. (2002). Steadystate pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-released morphine formulation in patients with chronic moderate-to-severe pain. Journal of Pain and Symptom Management, 23, 292-300.